Lipocine Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. The company develops drugs based on Hydroance, a drug delivery technology. It primarily focuses on developing oral versions of several hormones for use in men and women health; and various respiratory products for cough and cold conditions. The company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. It also offers custom drugs for pharmaceutical/biotechnology companies. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Clarus Therapeutics, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and is headquartered in Northbrook, IL.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Merck Sharp & Dohme BV, a subsidiary of Merck & Co., Inc., is a Dutch company located in Oss. The firm manufactures and distributes pharmaceutical products.

Manufactures pharmaceuticals and diagnostic substances

TesoRx is a virtual pharmaceutical company developing and commercializing pharmaceutical products. The company engages in developing and commercializing pharmaceutical products. It develops TSX-002, an oral therapeutic testosterone formulation for use in testosterone deficiency in men. The company was incorporated in 2010 and is based in Menlo Park, California.

TOLMAR is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products with specific focus in therapeutic areas of dental, dermatology, and oncology products.

Pantarhei Bioscience BV (PRB) is a limited liability company (Besloten Vennootschap) located in the Netherlands focussing on the development of innovative concepts for woman’s health and hormone-related cancer treatments. PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop treatments for Endocrine Cancer. PRB has developed a product pipeline based on its ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments and diseases such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer . PRB develops patent protected new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model of the Pantarhei companies is based on creating intellectual property (IP) of new concepts ad inventions, in-house project management and outsourcing of all research and development activities. After successful PoC, data and IP are licensed out to a licensee or partner for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.

Akzo Nobel NV is a holding company, which engages in the manufacture and sale of coating and paint products. engages in the production and marketing of paints and coatings. It operates through the following segments: Decorative Paintings, Performance Paintings, and Corporate and Others. The Decorative Paints segment manufactures and supplies a range of interior and exterior decoration and protection products for professional and do-it-yourself markets. The Performance Coatings segment produces automotive and aerospace; industrial; marine and protective; and powder coatings. The company was founded in 1792 and is headquartered in Amsterdam, Netherlands.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

Marius Pharmaceuticals is a biopharmaceutical company that develops oral testosterone replacement therapy to bring novel treatments to a range of diseases with unmet medical needs. The company's solutions overcome many of the problems associated with currently approved products and their proprietary delivery technology has reached optimal absorption with all meal types resulting in a higher bioavailability, providing men suffering from low testosterone with safe and efficacious treatment. The company was founded in 2017 and headquartered in Raleigh, North Carolina.

N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands.

Pharmasol Ltd., a subsidiary of OBG Pharmaceuticals Ltd., is a company headquartered in Liverpool, UK, that manufactures contract filler of small aerosols and pumps for pharmaceutical. The firm was founded in 1973. Bioglan Pharma Plc acquired Pharmasol Ltd. on September 01, 1997.\nThe company says this about itself: The principal activity of the company continued to be that of manufacture and distribution of over the counter products.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

R.P. Scherer GmbH & Co. KG, part of Catalent, Inc., is a company headquartered in Eberbach, Germany, that develops, manufactures and sells pharmaceutical products.

R.P. Scherer Technologies LLC, a subsidiary of Catalent, Inc., is an American company that develops, manufactures and sells oral, topical, sterile and inhaled forms of drug delivery products.